作者
Luis Paz-Ares, Alexander Luft, David Vicente, Ali Tafreshi, Mahmut Gümüş, Julien Mazières, Barbara Hermes, Filiz Çay Şenler, Tibor Csőszi, Andrea Fülöp, Jerónimo Rodríguez-Cid, Jonathan Wilson, Shunichi Sugawara, Terufumi Kato, Ki Hyeong Lee, Ying Cheng, Silvia Novello, Balazs Halmos, Xiaodong Li, Gregory M Lubiniecki, Bilal Piperdi, Dariusz M Kowalski
发表日期
2018/11/22
期刊
New England Journal of Medicine
卷号
379
期号
21
页码范围
2040-2051
出版商
Massachusetts Medical Society
简介
Background
Standard first-line therapy for metastatic, squamous non–small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong overall survival among patients with nonsquamous NSCLC.
Methods
In this double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC to receive 200 mg of pembrolizumab or saline placebo for up to 35 cycles; all the patients also received carboplatin and either paclitaxel or nanoparticle albumin-bound [nab]–paclitaxel for the first 4 cycles. Primary end points were overall survival and progression-free survival.
Results
After a median follow-up of 7.8 months, the median overall survival was 15.9 months (95% confidence …
学术搜索中的文章
L Paz-Ares, A Luft, D Vicente, A Tafreshi, M Gümüş… - New England Journal of Medicine, 2018